Organoid Model Predictive of Response to Immunotherapies
M
Mateusz Opyrchal, MD, PhD
Primary Investigator
Enrolling By Invitation
18 years and older
All
Phase
N/A
20 participants needed
1 Location
Brief description of study
What is the purpose of this study?
The purpose of this study is to create models out of tissue samples and treat those models
with the same immunotherapy treatment the patient will be receiving, in order to validatehis process and to predict responses to therapies and use it to choose the best treatmentshe future. The researchers will then examine the direct effects of thehose models.
THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.
Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:
IU Clinical Trials Office
Email: iutrials@iu.edu
Phone: (317) 278-5632
Detailed description of study
What will happen during the study?
- Drug: Immunotherapy
- Organoid samples will be collected at time of biopsy and cultured in the lab. The samples will then receive the same standard of care immunotherapy treatment as the patient.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Cancer
-
Age: 18 Years
-
Gender: All
Inclusion Criteria:
- ≥ 18 years old at the time of informed consent
- Ability to provide written informed consent and HIPAA authorization
- Biopsy proven diagnosis of cancer
- Able to obtain at least 2 16 gage cores of fresh tissue safely (3 or more coresd)
- Planning to undergo standard of care Immunotherapy
- Baseline standard of care CT within 8 weeks of starting Immunotherapy
Exclusion Criteria:
- Inability to provide fresh biopsy sample
- Any active infections
- Any conditions that in the opinion of treating physician and the study team willhe ability of the patient to receive prescribed treatment to assess the.
Updated on
01 Aug 2024.
Study ID: CTO-IUSCCC-0804, 17669
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
